Chronic heart failure

Clinical criteria:

• The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient,

AND

• Patient must be symptomatic with NYHA classes II, III or IV,

AND

• Patient must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 40%,

AND

• Patient must receive concomitant optimal standard chronic heart failure treatment, which must include a beta-blocker, unless at least one of the following is present in relation to the beta-blocker: (i) a contraindication listed in the Product Information, (ii) an existing/expected intolerance,

AND

• Patient must have been stabilised on an ACE inhibitor at the time of initiation with this drug, unless such treatment is contraindicated according to the TGA-approved Product Information or cannot be tolerated; OR

• Patient must have been stabilised on an angiotensin II antagonist at the time of initiation with this drug, unless such treatment is contraindicated according to the TGA-approved Product Information or cannot be tolerated.